Wearable Technology for Hyperglycemia and Heart Health in Duchenne Muscular Dystrophy
This observational study is looking at how wearable technology can help us understand hyperglycemia (high blood sugar) and heart rate variability (HRV, which reflects how well your heart adapts to different situations) in Duchenne Muscular Dystrophy (DMD). We want to see if these factors are linked to heart problems in DMD. You might be able to join if you are a male with DMD, at least 10 years old, and do not have diabetes. The study will measure your rate of hyperglycemia over 10 days at five different times, and your HRV over 7 days at five different times. This research could help us find better ways to screen for and treat heart issues in DMD. The study is currently unclear on its recruitment status and plans to enroll about 10 participants.
- Study design
- This is an observational study, meaning participants will be monitored without receiving a specific intervention beyond the wearable devices. It aims to enroll approximately 10 male participants.
- What's involved
- You would wear three different wearable devices. Your rate of hyperglycemia will be measured over 10 days at five time points, and your heart rate variability will be measured over 7 days at five time points.
- Compensation
- Not stated in the trial record.
- Follow-up
- Measurements for hyperglycemia are taken over 10 days at five time points, and for HRV over 7 days at five time points. It is unclear if there is follow-up beyond these measurement periods.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
At a glance
Conditions
NCT06093100
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Vanderbilt University Medical Center
Nashville, Tennesseestudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jaclyn Tamaroff, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Rate of hyperglycemia5 time points, each over 10 days
number of glucose measurements ≥140mg/dL over total number of glucoses
- Standard deviation of the mean R-to-R segment (SDANN)5 time points, each over 7 days
correlation of rate of hyperglycemia and SDANN, which reflects heart rate variability